Balance Sheet Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:34 2025-01-15 am EST			5-day change	1st Jan Change
984.90 ^INR	-1.52%		-1.59%	+1.36%

Jan. 10	Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	MT
Jan. 07	CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary	MT

70.4Yx7ga8ghHyipvOYzNfFBGSHyyc3-F9b_jpxtjtsLaI.o-Qpuctk0jb46ayggb-kTlPsvh97oTEXnWMB7mI5epCGzRTJ4U3zT8CLnA

Published financial data: ZYDUS LIFESCIENCES LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2020	2021	2022	2023	2024
Revenues	143B	151B	153B	172B	195B
Other Revenues, Total	-	-	-	-	-
Total Revenues	143B	151B	153B	172B	195B
Cost of Goods Sold, Total	50.8B	53.56B	56.86B	64.71B	63.94B
Gross Profit	91.73B	97.46B	95.8B	108B	132B
Selling General & Admin Expenses, Total	33.09B	33.27B	32.47B	37.65B	42.45B
Provision for Bad Debts	14M	17M	26M	1M	3M
Depreciation & Amortization - (IS)	6.94B	7.25B	7.13B	7.23B	7.64B
Other Operating Expenses	30.67B	30.68B	29.87B	34.26B	36.05B
Other Operating Expenses, Total	70.71B	71.22B	69.5B	79.14B	86.14B
Operating Income	21.02B	26.24B	26.29B	28.53B	45.39B
Interest Expense, Total	-3.24B	-1.6B	-1.14B	-1.26B	-440M
Interest And Investment Income	330M	508M	696M	768M	1.28B
Net Interest Expenses	-2.91B	-1.1B	-448M	-487M	841M
Income (Loss) On Equity Invest.	288M	474M	462M	946M	1.18B
Currency Exchange Gains (Loss)	-92M	9M	-71M	2.84B	806M
Other Non Operating Income (Expenses)	-6M	-33M	622M	251M	-11M
EBT, Excl. Unusual Items	18.3B	25.6B	26.86B	32.08B	48.21B
Restructuring Charges	-	-	-	-101M	-177M
Merger & Related Restructuring Charges	-442M	-	-	-	-
Impairment of Goodwill	-454M	-	-	-5.94B	-
Gain (Loss) On Sale Of Investments	725M	-187M	874M	596M	1.38B
Gain (Loss) On Sale Of Assets	-147M	-35M	-17M	208M	134M
Asset Writedown	-2.74B	-731M	-	-	-
Legal Settlements	-	-	-	-	-
Other Unusual Items	-	-1.32B	1.13B	-	-281M
EBT, Incl. Unusual Items	15.24B	23.32B	28.84B	26.84B	49.27B
Income Tax Expense	3.2B	1.47B	5.12B	5.88B	9.78B
Earnings From Continuing Operations	12.04B	21.85B	23.73B	20.96B	39.5B
Earnings Of Discontinued Operations	-	-	22.46B	-46M	230M
Net Income to Company	12.04B	21.85B	46.18B	20.92B	39.73B
Minority Interest	-278M	-514M	-1.31B	-1.32B	-1.13B
Net Income - (IS)	11.77B	21.34B	44.87B	19.6B	38.6B
Net Income to Common Incl Extra Items	11.77B	21.34B	44.87B	19.6B	38.6B
Net Income to Common Excl. Extra Items	11.77B	21.34B	22.42B	19.65B	38.36B
Per Share Items
Net EPS - Basic	11.49	20.84	43.83	19.3	38.14
Basic EPS - Continuing Operations	11.49	20.84	21.9	19.35	37.91
Basic Weighted Average Shares Outstanding	1.02B	1.02B	1.02B	1.02B	1.01B
Net EPS - Diluted	11.49	20.84	43.83	19.3	38.14
Diluted EPS - Continuing Operations	11.49	20.84	21.9	19.35	37.91
Diluted Weighted Average Shares Outstanding	1.02B	1.02B	1.02B	1.02B	1.01B
Normalized Basic EPS	10.9	15.12	15.12	18.45	28.66
Normalized Diluted EPS	10.9	15.12	15.12	18.45	28.66
Dividend Per Share	3.5	3.5	2.5	6	3
Payout Ratio	60.9	0.07	8.29	13.63	16.09
Supplemental Items
EBITDA	27.6B	33.04B	33.25B	35.34B	52.57B
EBITA	22.32B	27.51B	27.47B	29.34B	46.39B
EBIT	21.02B	26.24B	26.29B	28.53B	45.39B
EBITDAR	27.91B	33.26B	33.45B	35.57B	52.83B
Total Revenues (As Reported)	144B	151B	155B	174B	198B
Effective Tax Rate - (Ratio)	20.98	6.31	17.74	21.9	19.84
Total Current Taxes	2.38B	4.66B	4.42B	6.9B	14.93B
Total Deferred Taxes	821M	-3.18B	702M	-1.03B	-5.15B
Normalized Net Income	11.16B	15.48B	15.48B	18.73B	29B
Interest Capitalized	9.2B	7.05B	10.7B	6.81B	-
Interest on Long-Term Debt	2.62B	1.1B	286M	329M	33M
Non-Cash Pension Expense	344M	330M	213M	417M	375M
Supplemental Operating Expense Items
Advertising Expense	2.46B	2.54B	2.51B	2.57B	2.96B
Marketing Expenses	6.18B	5.61B	5.41B	7.19B	7.86B
Selling and Marketing Expenses	8.64B	8.15B	7.92B	9.76B	10.82B
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	10.99B	11.34B	10.46B	12.41B	13.12B
Net Rental Expense, Total	308M	219M	206M	229M	261M
Imputed Operating Lease Interest Expense	384M	240M	442M	545M	91.1M
Imputed Operating Lease Depreciation	-76.3M	-21.17M	-236M	-316M	170M
Maintenance & Repair Expenses, Total	1.6B	1.46B	1.4B	1.61B	1.66B

Fiscal Period: March	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	9.65B	8.88B	11.07B	5.73B	11.05B
Short Term Investments	687M	-	5.13B	-	-
Trading Asset Securities, Total	2.13B	1.99B	23.53B	6.19B	2.52B
Total Cash And Short Term Investments	12.46B	10.87B	39.74B	11.92B	13.58B
Accounts Receivable, Total	36.63B	31.27B	33.4B	44.17B	52.2B
Other Receivables	1.26B	2.82B	1.62B	2.18B	3.55B
Notes Receivable	-	-	-	4M	15M
Total Receivables	37.89B	34.09B	35.03B	46.35B	55.77B
Inventory	27.89B	32.36B	37.19B	34.13B	34.42B
Prepaid Expenses	761M	908M	721M	1.02B	1.02B
Other Current Assets, Total	8.15B	8.92B	9.94B	6.66B	9.41B
Total Current Assets	87.15B	87.16B	123B	100B	114B
Gross Property Plant And Equipment	93.2B	99.58B	103B	113B	120B
Accumulated Depreciation	-31.26B	-36.25B	-39.06B	-45.03B	-50.82B
Net Property Plant And Equipment	61.94B	63.33B	64.23B	68.27B	69.15B
Long-term Investments	5.52B	6.31B	9.35B	9.27B	9.7B
Goodwill	53.92B	53.46B	53.65B	48.04B	52.66B
Other Intangibles, Total	13.87B	12.36B	11.27B	10.9B	26.11B
Loans Receivable Long-Term	-	-	-	20M	-
Deferred Tax Assets Long-Term	8.53B	10.74B	10.96B	12.62B	16.44B
Other Long-Term Assets, Total	5.94B	5.47B	5.89B	8.35B	4.55B
Total Assets	237B	239B	278B	258B	293B
Liabilities
Accounts Payable, Total	20.31B	22.06B	21.38B	21.25B	21.27B
Accrued Expenses, Total	10.6B	11.12B	13.12B	15.45B	15.38B
Short-term Borrowings	38.26B	30.78B	33.14B	10.81B	7.86B
Current Portion of Long-Term Debt	9.45B	9.03B	5.2B	822M	-
Current Portion of Leases	129M	90M	88M	119M	105M
Current Income Taxes Payable	291M	884M	418M	1.57B	3.72B
Other Current Liabilities	3.65B	4.64B	5.05B	5.28B	5.08B
Total Current Liabilities	82.69B	78.61B	78.39B	55.31B	53.42B
Long-Term Debt	32.15B	6.1B	3.62B	-	-
Long-Term Leases	145M	151M	161M	198M	251M
Unearned Revenue Non Current	76M	227M	287M	295M	431M
Pension & Other Post Retirement Benefits	2.35B	3.1B	3.25B	2.72B	3.1B
Deferred Tax Liability Non Current	2.1B	1.2B	1.54B	1.94B	4.46B
Other Non Current Liabilities	250M	173M	165M	219M	10.13B
Total Liabilities	120B	89.55B	87.42B	60.68B	71.79B
Common Stock, Total	1.02B	1.02B	1.02B	1.01B	1.01B
Retained Earnings	104B	132B	173B	181B	206B
Comprehensive Income and Other	-1.32B	-2.84B	-3.88B	-7.02B	-8.77B
Total Common Equity	104B	130B	170B	175B	198B
Minority Interest	13.35B	19.37B	20.54B	21.72B	22.72B
Total Equity	117B	149B	191B	197B	221B
Total Liabilities And Equity	237B	239B	278B	258B	293B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.02B	1.02B	1.02B	1.01B	1.01B
ECS Total Common Shares Outstanding	1.02B	1.02B	1.02B	1.01B	1.01B
Book Value / Share	101.35	126.91	166.05	173.05	197.07
Tangible Book Value	35.97B	64.1B	105B	116B	120B
Tangible Book Value Per Share	35.14	62.61	102.64	114.81	118.78
Total Debt	80.14B	46.15B	42.21B	11.95B	8.22B
Net Debt	67.67B	35.28B	2.48B	27M	-5.36B
Debt Equivalent of Unfunded Proj. Benefit Obligation	2.58B	3.23B	3.43B	3.08B	3.48B
Debt Equivalent Oper. Leases	2.46B	1.75B	1.65B	1.83B	2.09B
Minority Interest, Total (Incl. Fin. Div)	13.35B	19.37B	20.54B	21.72B	22.72B
Equity Method Investments, Total	3.52B	3.57B	3.74B	4.17B	4.16B
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	10.41B	13.47B	14.44B	14.08B	11.86B
Inventories - Work In Process, Total	4.1B	4.59B	3.84B	4.6B	6.06B
Inventories - Finished Goods, Total	13.22B	14.22B	18.6B	15.46B	16.5B
Inventories - Others	154M	81M	313M	-	-
Land - (BS)	5.41B	5.7B	5.73B	6.26B	6.17B
Buildings, Total	18.84B	20.45B	19.69B	20.75B	21.91B
Machinery, Total	61.53B	65.6B	71.26B	74.98B	80.78B
Full Time Employees	25K	24.41K	23.74K	23.03K	26.92K
Accumulated Allowance for Doubtful Accounts (Supple)	217M	317M	305M	250M	456M

Fiscal Period: March	2020	2021	2022	2023	2024
Net Income	11.77B	21.34B	44.87B	19.6B	38.6B
Depreciation & Amortization - CF	5.42B	5.66B	5.91B	6.16B	6.35B
Amortization of Goodwill and Intangible Assets - (CF)	1.3B	1.27B	1.18B	809M	996M
Depreciation & Amortization, Total	6.72B	6.94B	7.09B	6.96B	7.34B
Amortization of Deferred Charges, Total - (CF)	240M	313M	275M	262M	296M
(Gain) Loss From Sale Of Asset	147M	35M	-1.11B	-208M	-169M
(Gain) Loss on Sale of Investments - (CF)	-725M	-89M	-751M	-483M	-409M
Asset Writedown & Restructuring Costs	3.19B	731M	-	6.04B	177M
Provision and Write-off of Bad Debts	40M	112M	41M	17M	206M
Net Cash From Discontinued Operations	-	-	-780M	-70M	292M
Other Operating Activities, Total	2.37B	1.69B	-25.08B	-2.88B	-5.34B
Change In Accounts Receivable	2.82B	4.32B	-1.82B	-8.48B	-7.47B
Change In Inventories	-1.01B	-4.8B	-5.26B	4.41B	-20M
Change In Accounts Payable	564M	1.71B	-1.2B	-1.71B	-448M
Change in Other Net Operating Assets	-1.08B	641M	4.76B	3.43B	-771M
Cash from Operations	25.05B	32.93B	21.04B	26.89B	32.28B
Capital Expenditure	-9.04B	-8.54B	-12.03B	-10.31B	-9.07B
Sale of Property, Plant, and Equipment	153M	71M	354M	394M	237M
Cash Acquisitions	-1.85B	-	-	-	-7.2B
Divestitures	-	1.04B	-	400M	550M
Sale (Purchase) of Intangible assets	-	-	1.13B	-	-
Investment in Marketable and Equity Securities, Total	285M	-299M	-7.09B	20.48B	-568M
Net (Increase) Decrease in Loans Originated / Sold - Investing	-	-	-	-24M	9M
Other Investing Activities, Total	330M	508M	29.18B	776M	1.29B
Cash from Investing	-10.12B	-7.22B	11.54B	11.71B	-14.75B
Short Term Debt Issued, Total	4.37B	-	2.91B	-	-
Long-Term Debt Issued, Total	-	-	7.46B	1.58B	14M
Total Debt Issued	4.37B	-	10.37B	1.58B	14M
Short Term Debt Repaid, Total	-	-6.42B	-	-23.06B	-3.1B
Long-Term Debt Repaid, Total	-7.86B	-25.68B	-14.22B	-9.96B	-827M
Total Debt Repaid	-7.86B	-32.11B	-14.22B	-33.02B	-3.93B
Repurchase of Common Stock	-	-	-	-8.63B	-7.25B
Common Dividends Paid	-7.17B	-15M	-3.72B	-2.67B	-6.21B
Common & Preferred Stock Dividends Paid	-7.17B	-15M	-3.72B	-2.67B	-6.21B
Other Financing Activities, Total	-287M	6.63B	-1.11B	-1.26B	-729M
Cash from Financing	-10.94B	-25.49B	-8.68B	-44B	-18.1B
Foreign Exchange Rate Adjustments	-	-42M	86M	66M	-231M
Miscellaneous Cash Flow Adjustments	-	-1.08B	-259M	-	60M
Net Change in Cash	3.99B	-905M	23.73B	-5.34B	-748M
Supplemental Items
Cash Interest Paid	-	1.91B	1.11B	1.26B	729M
Cash Income Tax Paid (Refund)	4.43B	3.45B	6.75B	5.92B	12.86B
Levered Free Cash Flow	11.77B	16.37B	6.85B	10.61B	16.1B
Unlevered Free Cash Flow	13.79B	17.37B	7.56B	11.4B	16.38B
Change In Net Working Capital	-2.73B	-2.26B	5.33B	3.35B	10.57B
Net Debt Issued / Repaid	-3.49B	-32.11B	-3.85B	-31.44B	-3.92B

Fiscal Period: March	2020	2021	2022	2023	2024
Profitability
Return on Assets	5.57	6.9	6.36	6.66	10.31
Return on Total Capital	6.68	8.35	7.68	8.08	12.95
Return On Equity %	10.3	16.4	13.96	10.82	18.9
Return on Common Equity	11.33	18.26	14.95	11.39	20.55
Margin Analysis
Gross Profit Margin %	64.36	64.53	62.75	62.46	67.29
SG&A Margin	23.22	22.03	21.27	21.84	21.72
EBITDA Margin %	19.37	21.88	21.78	20.5	26.89
EBITA Margin %	15.66	18.22	18	17.02	23.73
EBIT Margin %	14.75	17.38	17.22	16.55	23.22
Income From Continuing Operations Margin %	8.45	14.47	15.54	12.16	20.21
Net Income Margin %	8.26	14.13	29.4	11.37	19.74
Net Avail. For Common Margin %	8.26	14.13	14.68	11.4	19.63
Normalized Net Income Margin	7.83	10.25	10.14	10.87	14.84
Levered Free Cash Flow Margin	8.26	10.84	4.49	6.16	8.24
Unlevered Free Cash Flow Margin	9.68	11.5	4.95	6.61	8.38
Asset Turnover
Asset Turnover	0.6	0.63	0.59	0.64	0.71
Fixed Assets Turnover	2.35	2.41	2.39	2.6	2.85
Receivables Turnover (Average Receivables)	3.74	4.45	4.72	4.44	4.06
Inventory Turnover (Average Inventory)	1.86	1.78	1.63	1.81